Monopar Therapeutics Inc (MNPR) — Cash Flow-to-Debt Ratio
Monopar Therapeutics Inc (MNPR) has a Cash Flow-to-Debt Ratio of 0.00x as of December 2025, meaning its operating cash flow of $-3.37 Million could theoretically repay 0% of its total liabilities ($2.89 Billion) in one year. See Monopar Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Monopar Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Monopar Therapeutics Inc across 11 annual periods. Also explore Monopar Therapeutics Inc (MNPR) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Monopar Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Monopar Therapeutics Inc. For market capitalisation and broader financial context, see Monopar Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.22x | $-12.20 Billion | $2.89 Billion | ▼ -246.4% |
| 2024 | -1.22x | $-6.40 Million | $5.25 Million | ▲ +72.7% |
| 2023 | -4.47x | $-7.86 Million | $1.76 Million | ▼ -94.1% |
| 2022 | -2.30x | $-7.23 Million | $3.14 Million | ▲ +50.2% |
| 2021 | -4.63x | $-7.32 Million | $1.58 Million | ▼ -16.8% |
| 2020 | -3.96x | $-4.66 Million | $1.18 Million | ▲ +4.9% |
| 2019 | -4.17x | $-3.02 Million | $724.16K | ▲ +42.3% |
| 2018 | -7.23x | $-2.89 Million | $399.55K | ▲ +14.2% |
| 2017 | -8.42x | $-2.63 Million | $311.87K | ▲ +54.5% |
| 2016 | -18.52x | $-1.19 Million | $64.51K | ▼ -114.9% |
| 2015 | -8.62x | $-636.33K | $73.84K | — |